Regulatory Harmonization Takes Center Stage At IFPMA Asia Event
This article was originally published in PharmAsia News
Executive Summary
KUALA LUMPUR, Malaysia - Industry and regulators in Asia are mapping out strategies for regulatory harmonization, mostly borrowed from the U.S. and European Union experiences, in an effort to help the rapidly growing Asian pharmaceutical markets
You may also be interested in...
Would New Drug Launches Speed Up With A Pan-Asia Regulatory Framework? - Biopharma Asia Conference
SINGAPORE - As diseases like diabetes and cardiovascular complications - previously believed to be more prevalent in Western nations - are progressively spreading East to places like India and China, Asia-based pharmaceutical companies are pushing for a pan-Asian regulatory regime that can benefit its people with clear and obtainable goals
Would New Drug Launches Speed Up With A Pan-Asia Regulatory Framework? - Biopharma Asia Conference
SINGAPORE - As diseases like diabetes and cardiovascular complications - previously believed to be more prevalent in Western nations - are progressively spreading East to places like India and China, Asia-based pharmaceutical companies are pushing for a pan-Asian regulatory regime that can benefit its people with clear and obtainable goals
Forget China And India, Clinical Trial Opportunities In Malaysia and South Korea
The opportunities for clinical trials in China and India are well known to the pharmaceutical industry at this point, but Edward Ian, senior director of clinical operations for PRA International-Asia Pacific, wants company leaders to take notice and advantage of the potential in other countries in Asia Pacific